Loading...
XSHE
002007
Market cap4.00bUSD
Dec 05, Last price  
15.46CNY
1D
0.32%
1Q
-8.14%
Jan 2017
-56.76%
IPO
-20.92%
Name

Hualan Biological Engineering Inc

Chart & Performance

D1W1MN
XSHE:002007 chart
P/E
25.97
P/S
6.45
EPS
0.60
Div Yield, %
1.94%
Shrs. gr., 5y
0.12%
Rev. gr., 5y
3.43%
Revenues
4.38b
-18.02%
361,277,009352,991,929351,137,848475,162,7981,220,493,4291,261,620,656961,395,932972,460,2151,117,611,9991,243,487,9611,471,763,3081,934,669,6632,368,176,5693,216,898,7223,699,941,9905,023,206,2634,436,200,1254,516,979,4085,341,872,5574,379,196,621
Net income
1.09b
-26.57%
52,542,88779,001,163120,429,390187,258,195608,475,487612,360,499370,719,279299,787,871475,337,495538,417,396589,118,927780,312,519820,823,4711,139,512,9361,283,449,0491,613,105,2621,298,897,1641,076,265,2831,481,578,8491,087,850,982
CFO
1.06b
-21.29%
98,240,132131,429,335179,015,279161,175,908607,725,451609,531,570335,928,539494,692,263510,700,233497,148,698548,622,932329,938,357177,417,5221,292,636,1431,362,760,2811,325,292,9791,432,495,972957,311,9071,345,838,7811,059,345,161
Dividend
Jun 14, 20240.3 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People's Republic of China. Its blood products comprise human albumin, human immunoglobulin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin for external use, freeze-dried human fibrin glue for surgery, and human fibrinogen. The company's vaccines consist of influenza virus split vaccine, recombinant hepatitis B vaccine, ACYW135 meningococcal polysaccharide vaccine, A H1N1 influenza virus split vaccine, and quadrivalent influenza virus split vaccine. The company has strategic alliance with the Chinese Academy of Sciences, and other scientific research institutes and scientific research companies. The company was founded in 1992 and is based in Xinxiang, the People's Republic of China.
URL
https://www.hualanbio.com/
IPO date
Jun 25, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT